The Role of Immunotherapy in Pancreatic Cancer

Autor:	Reetu Mukherji, Dipanjan Debnath, Marion L. Hartley, Marcus S. Noel
Jazyk:	angličtina
Rok vydání:	2022
Předmět:	immunotherapy PD-1 PD-L1 pancreas cancer adenocarcinoma checkpoint inhibitor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Current Oncology, Vol 29, Iss 10, Pp 6864-6892 (2022)
Druh dokumentu:	article
ISSN:	1718-7729 1198-0052
DOI:	10.3390/curroncol29100541
Popis:	Pancreatic adenocarcinoma remains one of the most lethal cancers globally, with a significant need for improved therapeutic options. While the recent breakthroughs of immunotherapy through checkpoint inhibitors have dramatically changed treatment paradigms in other malignancies based on considerable survival benefits, this is not so for pancreatic cancer. Chemotherapies with modest benefits are still the cornerstone of advanced pancreatic cancer treatment. Pancreatic cancers are inherently immune-cold tumors and have been largely refractory to immunotherapies in clinical trials. Understanding and overcoming the current failures of immunotherapy through elucidating resistance mechanisms and developing novel therapeutic approaches are essential to harnessing the potential durable benefits of immune-modulating therapy in pancreatic cancer patients.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/e0de4312d2d74fea9aa43dc2880ffe95 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.